ArticleACS organic & inorganic Au2022
Effects of Ancillary Ligands on Deep Red to Near-Infrared Cyclometalated Iridium Complexes.
Article in ACS organic & inorganic Au, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Oxygen-responsive high-efficiency orange-red room-temperature phosphorescence from chalcogen-containing dibenzo[Chemical science · 2026Article
- In Pursuit of Low Energy Phosphorescence: Late Metal Coordination Complexes of the Planar, π-extended Bipyridyl Ligand 6,6',7,7'-Biphenanthridine.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Advances in Organic and Inorganic Photoredox Catalysis.ACS organic & inorganic Au · 2023Article
- Oxygen-Sensing Chemiluminescent Iridium(III) 1,2-Dioxetanes: Unusual Coordination and Activity.Analysis & sensing · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The design of organometallic compounds with efficient phosphorescence in the deep red to near-infrared portions of the spectrum is a long-standing fundamental challenge. Here we describe a series of heteroleptic bis-cyclometalated iridium complexes with phosphorescence in these low-energy regions of the spectrum. The cyclometalating ligands in this study feature a metalated benzothiophene aryl group substituted with a quinoline, isoquinoline, or phenanthridine heterocycle. Increasing the conjugation on the heterocycle stabilizes the ligand-centered LUMO, decreases the HOMO-LUMO gap, and enables phosphorescence to occur at long wavelengths. These cyclometalating ligands are paired with a variety of electron-rich ancillary ligands, such as dithiocarbamate (dipdtc), β-ketoiminate (acNac), β-diketiminate (NacNac), amidinate (dipba), and hexahydropyrimidopyrimidine (hpp), some of which have significant influences on the phosphorescence wavelength and excited-state dynamics. The syntheses of seven compounds in this series are described, three of which are structurally validated by single-crystal X-ray diffraction. Cyclic voltammetry reveals the effects of ligand modification on the frontier orbital energies. The photophysical properties of all compounds are thoroughly characterized by UV-vis absorption spectroscopy and steady-state photoluminescence at room-temperature and 77 K. Photoluminescence quantum yields and lifetimes of all compounds are reported.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.